
14 Murray Income Trust PLC
advantage of forced selling to add the company to the
portfolio. The significant growth potential in Germany and
high teens return on capital is under-appreciated by
reference to the very modest valuation. The holding in OSB
was exited following a number of disappointing trading
updates and a deteriorating view of the company’s
sustainable competitive advantage in its Precise
Mortgages division.
For the overseas-listed holdings we purchased a new
position in ASML, the Dutch listed global leader in
semiconductor lithography equipment. The company’s
extremely strong leadership position provides pricing
power, high returns on capital employed and good long-
term growth visibility, benefiting from the development of
Artificial Intelligence (AI). The initial purchase was poorly
timed at the start of the Year but we subsequently added
to the holding at a lower share price. We added a new
holding in Singapore-listed DBS, the largest bank in South
East Asia. We see the bank’s wealth management division
and the high return on equity derived from its fee income
and funding advantages as attractive quality
characteristics. The holding in Oversea-Chinese Banking
Corp was sold to fund DBS. Oversea-Chinese Banking
Corp had performed strongly during our period of
ownership, but we felt that DBS had stronger quality
characteristics and would be more likely to outperform in
future. The small holding in LVMH was sold from the
portfolio given concerns over potential earnings
downgrades due to struggling brand popularity, a weaker
consumer and the inability to push prices higher. Having
lost confidence in Novo Nordisk’s position in the GLP1
(weight loss) space we sold the modest holding. This
followed a series of negative efficacy updates for new
products such as CagriSema as well as falling prescription
numbers. Furthermore, Eli Lilly’s data for competitor
product Orforglipron had the potential to extend Eli Lilly’s
lead over Wegovy (Novo Nordisk’s weight loss produce).
Moreover, likely pricing pressure given the difference in
pricing for Wegovy in the US and in Europe had the
potential to impact profitability. Finally, the small holding in
VAT, the Swiss vacuum valve manufacturer, was sold on
concerns around a weaker demand backdrop, and in
particular, the potential impact of export restrictions on
sales to China.
In the FTSE 100, we repurchased LondonMetric,
the UK-
focused property business whose portfolio offers a high
degree of exposure to urban logistics. The stock has been
held in the portfolio previously, with the position sold at a
more expensive valuation around three years’ ago. We
now see the valuation and dividend yield as being at
attractive levels and are positive on the outlook for the
urban logistics sector given limited new supply and strong
rental growth potential. Rio Tinto, the global metals and
mining company, replaced the portfolio’s position in peer
BHP given its stronger medium term growth prospects and
more attractive valuation, including a higher dividend
yield. Reckitt Benckiser, the consumer health and hygiene
company, was added to the portfolio. The company is
progressing through a period of change with the
divestment of non-core businesses. In future, the
company will focus in on self-care, germ protection and
household care products which have strong brands and
market positions, and attractive growth prospects. Also,
during the year, the holding in Coca-Cola Hellenic was sold
following a period of strong performance and due to
concerns, regarding the level of profits derived from its
Russian operations. Following a profit warning in April we
purchased a holding in Bunzl. The company has long been
on our list of potential holdings, and we took the
opportunity presented by the announcement of weaker
trading in the United States. We believe the weaker
trading to be transitory and more than reflected in the
valuation with the share trading considerably below our
estimate of intrinsic value. Our investment in BP had been
due to the company’s alignment with the energy
transition, particularly compared to its peer Shell. However,
following a Capital Markets Day in February when the
company stepped back from its transition and
decarbonisation aspirations, we decided to sell the holding
and reinvest most of the proceeds in Shell. We view Shell
as being more defensive in a likely volatile oil price
environment particularly given its strong balance sheet
which provides confidence in the level of buybacks and
low breakeven oil price for the dividend. We sold the
holding in GSK reflecting the very modest prospects for
longer term earnings progression given the company’s
weak product pipeline and the increasing risks around
pricing pressure in the North American market.
Other transactions related to existing holdings were made
to take advantage of attractive valuation opportunities or
to reduce holdings following strong share price
performances and/or to manage large weights allowed
for the recycling of capital. We took advantage of share
price weakness to add to Coca-Cola EuroPacific Partners,
Haleon, Rotork, Kone, Safestore and Convatec, amongst
other holdings. Conversely, there were reductions to
holdings including to Accton Technology, AstraZeneca,
Howden Joinery, Intermediate Capital, London Stock
Exchange Group, Microsoft, RS and Unilever.
Investment Mana
er’s Report
Continued